Sanofi presents SARIL-RA-MOBILITY study results in RA for sarilumab at EULAR meeting

Sanofi and Regeneron Pharmaceuticals, Inc. presented positive results from a phase III trial (SARIL-RA-MOBILITY study) of investigational drug sarilumab in Rheumatoid Arthritis (RA) patients who were inadequate responders to methotrexate (MTX) therapy. New data presented at the meeting (EULAR 2014) showed that sarilumab increased major clinical response rates defined as achieving an ACR70 for at least 24 consecutive weeks and showed sustained improvement in signs and symptoms of RA after 52 weeks, which were secondary endpoints of the trial.